Zacks10d agobearish
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsIn the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
63last 24h
976last 7d
109● bullish (7d)
124● bearish (7d)
212publishers
Exec Edge19d agobearish
Cocrystal Pharma: The Strategic Reset Investors May Be MissingBy Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
Motley Fool24d agobearish
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy LiftingSince earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines.
Zacks38d agobearish
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher ExpensesTango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
Investor's Business Daily45d agobearish
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-UpGilead Sciences narrowly beat sales expectations for HIV PrEP drug Yeztugo. But Gilead stock remains trapped below two key lines.
Simply Wall St.72d agobearish
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued NarrativeGilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...
Zacks95d agobearish
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to KnowGilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close.
BioPharma Dive116d agobearish
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccineThe Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
Barrons.com134d agobearish
Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.
Reuters134d agobearish
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitionsBy Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for
